EURO SHOCK at a glance

As the first pan-European clinical study of its kind, EURO SHOCK is testing a novel intervention procedure aimed at reducing the high mortality associated with cardiogenic shock and alleviating its burden on chronic heart failure. The core aim of EURO SHOCK is therefore to test the early use of an Extracorporeal Membrane Oxygenation Machine (ECMO) to improve the poor outcomes seen in patients with cardiogenic shock.

TRIAL FACTS

EURO SHOCK is a prospective, open, multicentre randomised strategy trial in Cardiogenic Shock which will recruit patients presented with CGS secondary to Acute Coronary Syndrome at the recruiting centres involved in the trial.

TRIAL OBJECTIVES

Testing acute early up-front use of ECMO

Investigate whether benefits outweigh risks and complication

If effective, determine which patients benefit and if benefits are cost effective

EURO SHOCK will particularly focus on at risk and vulnerable sub groups such as the elderly and females as well as patients with multi-morbidity. The results of the study will proactively be used to contribute to standards, guidelines and clinical practices for treatment of patient with cardiogenic shock.